This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Millichap, J. J. Articles by Peterson, L. R. Search for Related Content PubMed PubMed Citation Articles by Millichap, J. J. Articles by Peterson, L. R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2001, p. 2719-2721, Vol. 39, No. 7
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.7.2719-2721.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Fluoroquinolone Resistance Is a Poor Surrogate Marker for Type II Topoisomerase Mutations in Clinical Isolates of Streptococcus pneumoniae

John J. Millichap,^1,2 Ekaterina Pestova,^1,2 Farida Siddiqui,^1,2 Gary A. Noskin,^1,2 and Lance R. Peterson^1,2,*

Departments of Pathology and Medicine, Northwestern University Medical School,¹ and Divisions of Microbiology and Infectious Diseases, Northwestern Memorial Hospital,² Chicago, Illinois 60611

Received 18 December 2000/Returned for modification 7 March 2001/Accepted 20 April 2001

The association between fluoroquinolone susceptibility and DNA mutations coding for amino acid substitutions in the quinolone resistance-determining region was assessed with 44 clinical isolates of Streptococcus pneumoniae. Twenty-three strains bore at least one amino acid substitution. Only seven strains with mutations were suggested by diminished susceptibility to ciprofloxacin (MIC, 2 µg/ml).

---

^* Corresponding author. Mailing address: Northwestern Prevention Epicenter, Department of Pathology, Galter Carriage House, Room 701, Northwestern Memorial Hospital, 251-East Huron, Chicago, IL 60611. Phone: (312) 926-2885. Fax: (312) 926-4139. E-mail: lancer{at}northwestern.edu.

---

Journal of Clinical Microbiology, July 2001, p. 2719-2721, Vol. 39, No. 7
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.7.2719-2721.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Epstein, B. J, Gums, J. G, Drlica, K. (2004). The Changing Face of Antibiotic Prescribing: The Mutant Selection Window. The Annals of Pharmacotherapy 38: 1675-1682 [Abstract] [Full Text]  
• Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
• Alonso, R., Galimand, M., Courvalin, P. (2004). An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 53: 682-683 [Full Text]  
• Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
• Jones, M. E., Critchley, I. A., Karlowsky, J. A., Blosser-Middleton, R. S., Schmitz, F.-J., Thornsberry, C., Sahm, D. F. (2002). In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV. Antimicrob. Agents Chemother. 46: 1651-1657 [Abstract] [Full Text]